ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ABIO ARCA Biopharma Inc

1.75
0.00 (0.00%)
Last Updated: 13:52:53
Delayed by 15 minutes

Period:

Draw Mode:

Volume 5,035
Bid Price 1.74
Ask Price 1.75
News -
Day High 1.76

Low
1.56

52 Week Range

High
2.16

Day Low 1.7316
Company Name Stock Ticker Symbol Market Type
ARCA Biopharma Inc ABIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.75 13:52:53
Open Price Low Price High Price Close Price Prev Close
1.76 1.7316 1.76 1.75
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
136 5,035 $ 1.75 $ 8,833 - 1.56 - 2.16
Last Trade Time Type Quantity Stock Price Currency
13:52:53 300 $ 1.75 USD

ARCA Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
25.38M 14.50M - 0 -5.34M -0.37 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ARCA Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ABIO Message Board. Create One! See More Posts on ABIO Message Board See More Message Board Posts

Historical ABIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.761.801.691.7527,594-0.01-0.57%
1 Month1.651.801.581.7027,8410.106.06%
3 Months1.641.801.561.6626,8300.116.71%
6 Months2.012.061.561.7625,223-0.26-12.94%
1 Year2.042.161.561.9024,321-0.29-14.22%
3 Years3.693.901.562.74119,628-1.94-52.57%
5 Years0.375122.000.298.12330,6311.37366.54%

ARCA Biopharma Description

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Your Recent History

Delayed Upgrade Clock